Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Searle CoKAR:SEARL -0.85%73 Days Inventory is 126.98 as of Mar. 2026, which is 12% above its 10-year median of 113.75. GuruFocus rates KAR:SEARL with a GF Score™ of 73/100 and a GF Value™ of ₨76.09 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, The Searle Co ranks better than 71.04% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). The Searle Co's Average Total Inventories for the
three
months ended in Mar. 2026 was ₨6,696 Mil. The Searle Co's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₨4,812 Mil.
Hence, The Searle Co's Days Inventory for the
three
months ended in Mar. 2026 was 126.98.
The historical rank and industry rank for The Searle Co's Days Inventory or its related term are showing as below:
KAR:SEARL'
s Days Inventory Range Over the Past 10 Years
Min: 88.33 Med: 113.75 Max: 166.26
Current: 119.51
During the past 13 years, The Searle Co's highest Days Inventory was 166.26. The lowest was 88.33. And the median was 113.75.
KAR:SEARL's Days Inventory is ranked better than 71.04% of 922
companies
in the Drug Manufacturers industry
Industry Median: 164.58
vs KAR:SEARL: 119.51
The Searle Co's Days Inventory
increased
from Mar. 2025 (105.21) to Mar. 2026 (126.98).
It might indicate that The Searle Co's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
The Searle Co's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.72.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The Searle Co's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.69.
The Searle Co (KAR:SEARL) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
The Searle Co's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The Searle Co's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
The Searle Co Days Inventory Related Terms
The Searle Co Days Inventory Historical Data
* Premium members only.
The historical data trend for The Searle Co's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:SEARL vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Searle Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Searle Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where The Searle Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Searle Co (KAR:SEARL) has a Days Inventory of 126.98 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on The Searle Co and its competitors. This is 12% above median its historical median of 113.75. Over the past decade, The Searle Co's Days Inventory has ranged from 88.33 to 166.26. According to the industry distribution chart, The Searle Co ranks #267 out of 922 companies in the Drug Manufacturers industry, placing it in the top 29%.
Is The Searle Co's Days Inventory too high?
The Searle Co's current Days Inventory of 126.98 is 12% above median its 10-year median of 113.75. Over the past 10 years, this metric has ranged from a low of 88.33 to a high of 166.26. The Drug Manufacturers industry median Days Inventory is 164.58. The Searle Co's value of 126.98 is 22.8% below this industry median. Based on the distribution chart, The Searle Co ranks #267 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, The Searle Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Searle Co's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, The Searle Co ranks #267 out of 922 companies for Days Inventory. This puts The Searle Co in the upper half of its industry. The industry median Days Inventory is 164.58. The Searle Co's value of 126.98 is 22.8% below this benchmark. Historically, The Searle Co's own Days Inventory has ranged from 88.33 to 166.26 over the past decade. While the company's 10-year median is 113.75 vs. the industry median of 164.58, The Searle Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.58, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Searle Co's current Days Inventory of 126.98 is 22.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on The Searle Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Searle Co's current Days Inventory is 126.98, which is 12% above median its own 10-year median of 113.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Searle Co stock overvalued right now?
Based on GuruFocus' analysis, The Searle Co (KAR:SEARL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨76.09, compared to a current price of ₨91.52 — trading 20.3% above its estimated fair value. The current Days Inventory is 126.98, which is 12% above median its 10-year median of 113.75 and 22.8% below the Drug Manufacturers industry median of 164.58. The Searle Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For The Searle Co (KAR:SEARL), the current Days Inventory is 126.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Searle Co (KAR:SEARL) Overvalued in 2026?
Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued.
The current stock price of ₨91.52 is trading 20.3% above its estimated GF Value™ of ₨76.09.
GuruFocus considers The Searle Co to be Modestly Overvalued.
Key valuation signals for KAR:SEARL:
Days Inventory: 126.98 (12% above median its 10-year median of 113.75)
GF Value™: ₨76.09 vs. price of ₨91.52 (20.3% above fair value)
Industry Position: 22.8% below the Drug Manufacturers median (#267 of 922)
No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
73GF Score
Get the complete analysis for KAR:SEARL
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:SEARL has been successfully added to your 
